Should I buy Cencora (COR) stock or is it too late?

Cencora · Health Care · price $330

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $346 (+4.8 %), call made on August 8, 2026, maturing on August 8, 2027 (67 d ago).

The 6 reliable analysts $389+18 %

The 5 other firms $339+2.7 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $389 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Cencora

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Baird	80 %	+24.3 %	5	$339 +3%

In short — Should you invest in Cencora? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $350, i.e. +6%), and the most reliable on COR targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 12 ratings) — a sign of market conviction.
The most reliable firm on COR, Evercore ISI Group (100% hit rate, 2 scored calls), targets $350 (call made on August 6, 2026, maturing on August 6, 2027) (+6%) in its most recent call, and $420 (call made on February 5, 2026, maturing on February 5, 2027) (+27%) in the one coming due soonest.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 12 ratings, 3 are neutral.
Limited upside: the median target is only +6% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on COR

Median target $350 (+6%) · 12 ratings · Buy consensus

Strong Buy00%

Buy975%

Hold325%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Cencora now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $350 (+6%), and Evercore ISI Group (most reliable on COR, 100%) targets $350. Weigh that against valuation (P/E ~24). This is not personalized advice.

Is it too late to invest in Cencora?

Not according to analysts: the median target ($350) is still +6% above the current price ($330) (most reliable on COR: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Cencora still worth investing in?

It depends on the gap between the price ($330) and its estimated value: analysts target $350 on median (+6%), with 75% buys (most reliable on COR: Evercore ISI Group, 100%). Cross-check with their real reliability on COR and the cautions above. Information, not advice.

What's the main risk in buying COR?

The consensus is not unanimous: of 12 ratings, 3 are neutral.

→ Go deeper: the full Cencora profile (consensus, analyst reliability, price target, performance).